EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 8, 2019, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company’s NDA. For more information, visit www.zogenix.com.
Senior Director, Corporate Communications
Public Relations, Syneos Health
+1 (858) 449 9575 | email@example.com
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com